Drug Trial Radar · NCT05919680
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jan 15, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- NorthSea Therapeutics B.V.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once daily (QD) oral administration of 800 mg (32 mL solution) NST-6179 or placebo for 4 weeks. The NST-6179 dose for Part B is planned to be 1200 mg QD for 12 weeks. Actual dose, however, will be determined during the safety review meeting.
Conditions
- Intestinal Failure Associated Liver Disease
Interventions
NST-6179 Part ADrug
Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
NST-6179 Part BDrug
Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
Matched PlaceboOther
Matched placebo for administration in Part A or Part B
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of NST-6179Time frame: Up to 14 Weeks
- To assess the pharmacokinetics of NST-6179Time frame: Day 1 and Day 14
- To assess the pharmacodynamic effects of NST-6179 on hepatic steatosisTime frame: 12 weeks
- To assess the pharmacodynamic effects of NST-6179 on hepatic inflammationTime frame: 12 weeks
- To assess the pharmacodynamic effects of NST-6179 on hepatic cholestasis (bilirubin, ALP, GGT)Time frame: 12 weeks
- To assess the pharmacodynamic effects of NST-6179 on hepatic fibrosis (ELF, Pro-C3, FIB-4)Time frame: 12 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale Campus
Scottsdale, Arizona · Recruiting
University of California San Francisco Medical Center
San Francisco, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Not yet recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
The University of Chicago Medical Center
Chicago, Illinois · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Mayo Clinic Rochester Campus
Rochester, Minnesota · Recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
The Cleveland Clinic
Cleveland, Ohio · Recruiting
Vanderbilt University School of Medicine
Nashville, Tennessee · Recruiting
University of Washington
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.